Akebia Broadens its Pipeline by Licensing J&J’s HIF-Based Portfolio

By Jawala Prasad

Pharma Deals Review: Vol 2017 Issue 3 (Table of Contents)

Published: 29 Mar-2017

DOI: 10.3833/pdr.v2017.i3.2233     ISSN: 1756-7874

Section: Licensing



Akebia Therapeutics has partnered with Johnson and Johnson’s Janssen Pharmaceutica to explore a library of well-characterised molecules based on hypoxia-inducible factor (HIF) biology in a deal potentially worth more than US$230 M...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details